Osimertinib in untreated epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer.

about

Osimertinib in untreated epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer.

Item

http://www.wikidata.org/entity/Q54959395

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Osimertinib in untreated epide ...... ed non-small cell lung cancer.

@en

Osimertinib in untreated epidermal growth factor receptor

@nl

type

Item

label

Osimertinib in untreated epide ...... ed non-small cell lung cancer.

@en

Osimertinib in untreated epidermal growth factor receptor

@nl

prefLabel

Osimertinib in untreated epide ...... ed non-small cell lung cancer.

@en

Osimertinib in untreated epidermal growth factor receptor

@nl

P1476

Osimertinib in untreated epide ...... ed non-small cell lung cancer.

@en

P2093

Chiara Lazzari

http://www.w3.org/2001/XMLSchema#string

Mariacarmela Santarpia

http://www.w3.org/2001/XMLSchema#string

Niki Karachaliou

http://www.w3.org/2001/XMLSchema#string

Vanesa Gregorc

http://www.w3.org/2001/XMLSchema#string

P2860

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial.

The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.

Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance.

Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer.

P304

S165-S170

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.21037/TLCR.2018.03.19

http://www.w3.org/2001/XMLSchema#string

P433

Suppl 2

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Rafael Rosell

P577

2018-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29782558

http://www.w3.org/2001/XMLSchema#string

P921

osimertinib

P932

5943214

http://www.w3.org/2001/XMLSchema#string